FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a new compound which has the general formula (I) or a pharmaceutically acceptable salt thereof.
EFFECT: compound of formula (I) can be used as a medicinal product for the treatment or prevention of cancer caused by BRAF mutants.
13 cl, 8 dwg, 10 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BRAF INHIBITORS AS "PARADOX BREAKERS" | 2020 |
|
RU2825870C1 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| METHOD FOR ADJUVANT THERAPY OF CANCER | 2013 |
|
RU2640180C2 |
| NEW BRAF INHIBITORS AND THEIR USE FOR TREATMENT OF SKIN REACTIONS | 2018 |
|
RU2779185C2 |
